Study of MK-7162 in Combination With Pembrolizumab (MK-3475) in Adult Participants With Advanced Solid Tumors (MK-7162-002)
Status:
Completed
Trial end date:
2020-10-19
Target enrollment:
Participant gender:
Summary
The purposes of this study are to: 1) determine the safety and tolerability of MK-7162 when
administered in combination with pembrolizumab (MK-3475), 2) establish a preliminary
recommended Phase 2 dose (RP2D) of MK-7162 when administered in combination with
pembrolizumab, and 3) assess the pharmacokinetics and pharmacodynamics of MK-7162 when
administered in combination with pembrolizumab and other therapies to adult participants with
advanced solid tumors.